Our follow-on program, EX597, is derived from a novel family of global FAAH inhibitors. EX597, is licensed to and being developed by a specialty German Pharma company for the treatment of social anxiety and PTSD. PTSD is a disease with a significant unmet medical need and a market size projected to be approximately $1.7 billion.
EX597 is designed to block the FAAH enzyme, similar to EX937, thereby preventing degradation of anandamide and leading to increased receptor signaling. In contrast to EX937, the EX597 readily enter the CNS, which enables treatment of neurological disorders such as PTSD, addiction, anxiety and insomnia.